Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.
暂无分享,去创建一个
[1] E. Bröcker,et al. Granulocyte‐derived elastase and gelatinase B are required for dermal–epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid , 2004, The Journal of pathology.
[2] S. Tsirka,et al. Involvement of Tissue Plasminogen Activator in Onset and Effector Phases of Experimental Allergic Encephalomyelitis , 2002, The Journal of Neuroscience.
[3] M. Polette,et al. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. , 2001, The Journal of investigative dermatology.
[4] M. G. Fleming,et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. , 2001, The Journal of clinical investigation.
[5] P. Carmeliet,et al. Tissue-Type Plasminogen Activator Deficiency Exacerbates Arthritis1 , 2001, The Journal of Immunology.
[6] T. Bugge,et al. Plasminogen activators direct reorganization of the liver lobule after acute injury. , 2001, The American journal of pathology.
[7] S. Maxwell,et al. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. , 2001, Journal of cell science.
[8] Z. Werb,et al. The Serpin α1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo , 2000, Cell.
[9] T. Bugge,et al. Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice. , 2000, Methods.
[10] P. Carmeliet,et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. , 2000, The American journal of pathology.
[11] D. Witte,et al. Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[12] B. Nielsen,et al. Functional overlap between two classes of matrix‐degrading proteases in wound healing , 1999, The EMBO journal.
[13] D. Collen. The Plasminogen (Fibrinolytic) System , 1999, Thrombosis and Haemostasis.
[14] H. Lijnen,et al. Matrix Metalloproteinase System Deficiencies and Matrix Degradation , 1999, Thrombosis and Haemostasis.
[15] J. Sipley,et al. Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.
[16] Z. Werb,et al. Gelatinase B–deficient Mice Are Resistant to Experimental Bullous Pemphigoid , 1998, The Journal of experimental medicine.
[17] P. Carmeliet,et al. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[18] R. Nagle,et al. Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. , 1998, The Biochemical journal.
[19] Gabriele Bergers,et al. MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.
[20] T. Bugge,et al. Ligneous conjunctivitis in plasminogen-deficient mice. , 1998, Blood.
[21] Z. Werb. ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.
[22] K. Fang,et al. Dog Mast Cell α-Chymase Activates Progelatinase B by Cleaving the Phe88-Gln89 and Phe91-Glu92 Bonds of the Catalytic Domain* , 1997, The Journal of Biological Chemistry.
[23] W. Kao,et al. Healing of corneal epithelial defects in plasminogen- and fibrinogen-deficient mice. , 1997, Investigative ophthalmology & visual science.
[24] D. Witte,et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. , 1997, Blood.
[25] C. López-Otín,et al. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). , 1997, European journal of biochemistry.
[26] G. Till,et al. A major role for neutrophils in experimental bullous pemphigoid. , 1997, The Journal of clinical investigation.
[27] L. Zanetta,et al. Control of type IV collagenase activity by components of the urokinase–plasmin system: a regulatory mechanism with cell‐bound reactants , 1997, The EMBO journal.
[28] P. Carmeliet,et al. Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic Glomerulonephritis , 1997, The Journal of experimental medicine.
[29] P. M. Wilson,et al. Changes in rat corneal matrix metalloproteinases and serine proteinases under vitamin A deficiency. , 1997, Current eye research.
[30] W. Nauseef,et al. Isolation and Functional Analysis of Neutrophils , 1996, Current protocols in immunology.
[31] P. Carmeliet,et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[32] L. Lund,et al. Impaired wound healing in mice with a disrupted plasminogen gene , 1996, Nature Medicine.
[33] S. E. Brodie. New York, New York, USA , 1996 .
[34] R. Fridman,et al. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). , 1995, Cancer research.
[35] T. Bugge,et al. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. , 1995, Genes & development.
[36] G. Till,et al. The role of complement in experimental bullous pemphigoid. , 1995, The Journal of clinical investigation.
[37] K. Imai,et al. Matrix Metalloproteinase 7 (Matrilysin) from Human Rectal Carcinoma Cells , 1995, The Journal of Biological Chemistry.
[38] W. Parks,et al. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. , 1994, The Journal of clinical investigation.
[39] P. Carmeliet,et al. Physiological consequences of loss of plasminogen activator gene function in mice , 1994, Nature.
[40] C. Soria,et al. Activation of the 92 kDa type IV collagenase by tissue kallikrein , 1993, Journal of cellular physiology.
[41] J. Troy,et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. , 1993, The Journal of clinical investigation.
[42] M. Kramer,et al. The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. , 1993, The Journal of clinical investigation.
[43] F. Wojnarowska,et al. An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid , 1993, Clinical and experimental dermatology.
[44] J. Reynolds,et al. The Role of Plasmhogen Activators in the Regulation of Connective Tissue Metalloproteinases a , 1992 .
[45] K. Naka,et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. , 1992, The Journal of biological chemistry.
[46] L. Diaz,et al. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. , 1992, The Journal of investigative dermatology.
[47] M. Kramer,et al. Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid , 1992, The British journal of dermatology.
[48] A. Strongin,et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. , 1992, The Journal of biological chemistry.
[49] J. Enghild,et al. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. , 1992, The Journal of biological chemistry.
[50] J. Uitto,et al. Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. , 1991, The Journal of biological chemistry.
[51] D. Parry,et al. Comparison of molecularly cloned bullous pemphigoid antigen to desmoplakin I confirms that they define a new family of cell adhesion junction plaque proteins. , 1991, The Journal of biological chemistry.
[52] D. Belin,et al. mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. , 1990, The Journal of investigative dermatology.
[53] W. Saunders,et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. , 1990, The Journal of clinical investigation.
[54] S. Grando,et al. Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. , 1989, Archives of dermatology.
[55] P. Jensen,et al. Epidermal plasminogen activator is abnormal in cutaneous lesions. , 1988, The Journal of investigative dermatology.
[56] E. Bauer,et al. Elevated levels of human collagenase inhibitor in blister fluids of diverse etiology. , 1986, The Journal of investigative dermatology.
[57] S. Weiss,et al. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[58] J. Uitto,et al. Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. , 1983, The Journal of investigative dermatology.
[59] D. Priebat,et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. , 1982, The Journal of investigative dermatology.
[60] M. Mihm,et al. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. , 1982, The Journal of investigative dermatology.
[61] Z. Werb,et al. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. , 1977, The New England journal of medicine.
[62] C. Orfanos,et al. Electron microscopic study of bullous pemphigoid. , 1972, Archives of dermatology.
[63] T. Brenn,et al. Fitzpatrick’s Dermatology in General Medicine , 2007 .
[64] J. Woessner,et al. Matrix metalloproteinases and TIMPs , 2000 .
[65] S. Shapiro,et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. , 2000, The Journal of clinical investigation.
[66] P. Carmeliet,et al. Role of plasminogen system components in focal cerebral ischemia , 1999 .
[67] H. Kirschke,et al. Chromogenic Peptide Substrates , 1999 .
[68] K. Washington,et al. Liver regeneration is transiently impaired in urokinase-deficient mice. , 1998, The American journal of physiology.
[69] P. Carmeliet,et al. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. , 1998, Blood.
[70] E. Coligan. Current protocols in immunology , 1991 .
[71] Gammon Wr. Immune complex and complement-mediated leukocyte recruitment in bullous pemphigoid. , 1989 .
[72] S. Grando,et al. Cytotoxic proteases in blister fluid of pemphigus and pemphigoid patients. , 1989, International journal of tissue reactions.
[73] P. Friberger. Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. , 1982, Scandinavian journal of clinical and laboratory investigation. Supplementum.
[74] Thomas B. Fitzpatrick,et al. Dermatology in general medicine , 1971 .